Drug Profile

CLR 2200 - Cellectar Biosciences/Traws Pharma

Alternative Names: CLR 2200

Latest Information Update: 04 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellectar Biosciences; Onconova Therapeutics
Developer Cellectar Biosciences; Traws Pharma
Class Antineoplastics; Drug conjugates; Phospholipid ethers; Small molecules
Mechanism of Action Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
28 Oct 2021 No recent reports of development identified for research development in Solid-tumours in USA
09 Mar 2021 Cellectar Biosciences has patent protection for Phospholipid-ether analogues in Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com